The efficacy of tumor-specific antigen vaccines may be influenced by immune checkpoint suppression mechanisms, such as PD-1/PD-L1 attenuating antigen presentation and impeding T cell-mediated cytotoxicity 67. Here, CD274 is linked to neoplasm.